TORONTO, June 17, 2021 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a leading drug development company focused on low-dose psychedelic therapies for mental health, is pleased to announce the selection of BioPharma Services Inc. (“BioPharma”), as the contract research organization (CRO) for its Phase 1 clinical trial. The proposed study, titled “A Randomized, Double-Blind…


Previous articleAwakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release From Escrow Of Private Placement Proceeds, And Final Approval For Listing On Neo Exchange
Next articleatai Life Sciences Announces Pricing of Upsized Initial Public Offering